Datum Källa Rubrik Typ Alternativ
2023-07-24 Ziccum Ziccum säkrar andra Feasibility-avtalet på två månader: VD-intervju på svenska Pressreleaser Ladda ner | Visa Stäng
2023-07-20 Ziccum Ziccums Q2-rapport - VD-uppdatering på svenska Pressreleaser Ladda ner | Visa Stäng
2023-07-18 Ziccum ZICCUM AB (publ) Interim report Q2 2023 Rapporter Ladda ner | Visa Stäng
2023-07-17 Ziccum Ziccum signs Evaluation Agreement for Feasibility Study with major global Pharmaceutical Corporation Pressreleaser Ladda ner | Visa Stäng
2023-06-19 Ziccum Ziccum sponsors the Global mRNA-Based Therapeutics Summit, Boston MA, July 26-28 Pressreleaser Ladda ner | Visa Stäng
2023-06-05 Ziccum Ziccum joint proposal not selected for detailed application in current CEPI Call Pressreleaser Ladda ner | Visa Stäng
2023-06-02 Ziccum Ziccum appoints senior biopharma executive as new CFO Pressreleaser Ladda ner | Visa Stäng
2023-05-30 Ziccum Ziccum AB: BioStock Life Science Spring Summit med Ziccum Pressreleaser Visa Stäng
2023-05-30 Ziccum Ziccum AB: BioStock Life Science Spring Summit with Ziccum Pressreleaser Visa Stäng
2023-05-26 Ziccum Aerosol and inhalation authority Per Gerde joins Board of Directors of Ziccum AB Pressreleaser Ladda ner | Visa Stäng
2023-05-25 Ziccum Ziccum CEO to present at BioStock Life Science Spring Summit Pressreleaser Ladda ner | Visa Stäng
2023-05-24 Ziccum Kommuniké från årsstämma i Ziccum AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-24 Ziccum Bulletin from the Annual General Meeting of Ziccum AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-11 Ziccum Strategin ger resultat med betald studie i samarbete med toppbolag: VD-intervju på svenska Pressreleaser Ladda ner | Visa Stäng
2023-05-09 Ziccum Ziccum signs Evaluation Agreement with Biopharmaceutical Corporation focused on mRNA technologies Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 9 May 2023 | Ziccum

Ziccum signs Evaluation Agreement with Biopharmaceutical Corporation focused on mRNA technologies

Ziccum AB (publ) (‘Ziccum’) has signed an Evaluation agreement with a Biopharmaceutical Corporation focused on mRNA technologies to commence a Feasibility study regarding LaminarPace for ambient drying of mRNA/LNP materials and/or mRNA vaccine(s). mRNA is a top strategic priority for Ziccum, and in March 2023 it announced positive results in its in-house project, drying active mRNA in LNP formulation.

Ziccum AB (publ) (‘Ziccum’) has signed an Evaluation agreement with a Biopharmaceutical Corporation focused on mRNA technologies. This new agreement is for a fully financed Feasibility study, formulating and drying mRNA/LNP materials with LaminarPace ambient drying.

The Evaluation agreement signing is a milestone achievement in one of the highlighted partnering dialogues in Ziccum’s regularly updated Project Portfolio overview. Since 2022, following new leadership and a significant strategic refocus, Ziccum has successfully pursued a dynamic partnering agenda, creating a pipeline of industrial dialogues.

The agreement is the result of keen interest in the LaminarPace technology to generate dry powder materials in mRNA/LNP technology development. This is based on successful results on the mRNA/LNP platform for LaminarPace, an entirely new drying technology making dry powder biopharmaceuticals possible. The Feasibility study is expected to start in May 2023.

CEO Ann Gidner: “We are delighted to sign this agreement with such an important, leading mRNA player and to continue work in this highly interesting field. For us at Ziccum this collaboration confirms the strong interest for our novel technology, enabling thermostable biopharmaceuticals in general and the most fragile mRNA/LNP in particular, and it confirms our outreach in the international Pharma industry. We are indeed excited to move forward.”

Chairman Fredrik Sjövall: “This agreement is a breakthrough for Ziccum and a strong acknowledgement of what our technology can offer the key players in this industry. It also confirms our new strategy, business model and capability to move partnering dialogues forward, thanks to the combination of good leadership and strong technical data being generated in well-defined internal trials.”

2023-05-09 Ziccum Ziccums Q1-resultat: VD-uppdatering på svenska Pressreleaser Ladda ner | Visa Stäng
2023-05-08 Ziccum KOMPLETTERING TILL KALLELSEN TILL ÅRSSTÄMMA I ZICCUM AB (PUBL), ATT HÅLLAS DEN 24 MAJ 2023, KL. 11.00 I BOLAGETS LOKALER PÅ SCHEELEVÄGEN 22 I LUND Pressreleaser Ladda ner | Visa Stäng
2023-05-02 Ziccum Ziccum AB filing three patent applications as part of new, expanded strategy to strengthen patent protection Pressreleaser Ladda ner | Visa Stäng
2023-04-26 Ziccum ZICCUM AB (publ) releases Interim report Q1 2023 Rapporter Ladda ner | Visa Stäng
2023-04-24 Ziccum KALLELSE TILL ÅRSSTÄMMA I ZICCUM AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-03-20 Ziccum Ziccum reports positive results from drying of active mRNA and promising mRNA activity after powder reconstitution Pressreleaser Ladda ner | Visa Stäng
2023-03-17 Ziccum Ziccum to attend BIO-Europe Spring in Basel Pressreleaser Ladda ner | Visa Stäng
2023-03-10 Ziccum Ziccum AB joins innovative financial platform for Investor Relations management and European outreach Pressreleaser Ladda ner | Visa Stäng
2023-02-17 Ziccum ZICCUM AB (publ) releases Annual Report 2022 Rapporter Ladda ner | Visa Stäng
2023-01-27 Ziccum ZICCUM AB (publ) Year-end report Q4 2022 Analyser Ladda ner | Visa Stäng
2023-01-23 Ziccum Ziccum submits Expression of Interest for CEPI funding Analyser Ladda ner | Visa Stäng
2023-01-18 Ziccum Ziccum CEO to present at international mRNA Summit in Berlin Analyser Ladda ner | Visa Stäng
2022-12-16 Ziccum Ziccum awarded 10 MSEK Eurostars funding for 3D-modeling and Digital twin project Analyser Ladda ner | Visa Stäng
2022-12-14 Ziccum Ziccum launches new, expanded website Analyser Ladda ner | Visa Stäng
2022-12-08 Ziccum Ziccum signs agreement with Zurich University of Applied Sciences on advanced 3D-modeling project Analyser Ladda ner | Visa Stäng
2022-10-28 Ziccum Ziccums Q3-resultat: VD-uppdatering på svenska Analyser Ladda ner | Visa Stäng
2022-10-27 Ziccum ZICCUM AB (publ) Interim report Q3 2022 Analyser Ladda ner | Visa Stäng
2022-10-24 Ziccum Ziccum generates proof of successful drying of lipid nanoparticles in mRNA project Analyser Ladda ner | Visa Stäng
2022-09-27 Ziccum Ziccum reopens application for CEPI funding on thermostable vaccines with new partner Analyser Ladda ner | Visa Stäng
2022-09-23 Ziccum Ziccum receives results from evaluation study with leading Pharmaceutical Corporation Analyser Ladda ner | Visa Stäng
2022-09-14 Ziccum Ziccum and Zurich University of Applied Sciences submit joint application for Eurostars funding Analyser Ladda ner | Visa Stäng
2022-09-01 Ziccum Ziccum on the move: company to attend major industry events across Europe in 2022 Analyser Ladda ner | Visa Stäng
2022-08-23 Ziccum ZICCUM AB (publ) Interim report Q2 2022 Analyser Ladda ner | Visa Stäng

Kommande händelser

29 Apr 2024 | Kvartalsrapport 2024-Q1
17 May 2024 | Årligutdelning
30 Jul 2024 | Kvartalsrapport 2024-Q2
29 Oct 2024 | Kvartalsrapport 2024-Q3
29 Jan 2025 | Bokslutskommuniké 2024